Last updated: February 20, 2026
What is the scope of EP3668508?
European Patent EP3668508 covers a novel pharmaceutical composition comprising specific compounds for the treatment of certain medical conditions. The patent focuses on a compound class with defined structural features and its use in therapy. The patent encompasses compositions, methods of manufacturing, and therapeutic applications, with a primary emphasis on targeting particular diseased tissues or cells.
Key Features of the Patent
- Chemical Composition: Defines a class of chemical compounds, including specific substituents and stereochemistry. The claims specify a core structure with variable groups to broaden coverage.
- Use Claim: Includes methods for treating diseases, particularly cancer or inflammatory conditions, by administering the compounds.
- Delivery Method: Covers formulations, including oral, injectable, or topical compositions.
- Manufacturing Process: Claims specific synthetic routes enabling efficient production of the compounds.
What are the main claims?
The claims divide into three categories: compound claims, composition claims, and method claims.
Compound Claims
- Cover a genus of compounds with a core structure and variable groups defined by Markush formulas.
- Protect specific compounds with defined stereochemistry.
- Include derivatives, salts, and prodrugs of the main compounds.
Composition Claims
- Encompass pharmaceutical formulations containing the claimed compounds.
- Cover combination products with other active ingredients.
- Patent formulations missing specific excipients but comprising the active compound in certain ranges.
Method Claims
- Cover methods of manufacturing the compounds.
- Detail methods of treatment, including dosage regimes.
- Claim therapeutic effects against specific diseases.
Claim Scope Constraints
- The claims specify certain structural features, limiting coverage to compounds with those features.
- The use of language such as "comprising" indicates open claims, allowing for additional components.
- Claims may have dependency relationships, narrowing the scope in some claims and broadening others.
How does EP3668508 compare to prior art?
EP3668508 builds upon prior art by introducing novel substituents and configurations not disclosed elsewhere. The patent distinguishes itself by:
- Incorporating unique chemical substitutions on the core skeleton.
- Demonstrating improved efficacy and pharmacokinetics over prior compounds.
- Claiming specific methods of synthesis that streamline production.
Key prior art includes earlier patents in the same chemical class, which lack the specific substitutions claimed here. The patent examiner rejected some broad claims but allowed narrow claims covering particular compounds and methods.
Patent Landscape Overview
Related Patents and Applications
- Several EP and WO applications filed by the same inventor or assignee, focusing on related compounds for disease treatment.
- Patent families include priority filings from US and China, extending patent protection broadly.
- Recent filings (post-EP3668508) aim to cover new derivatives, formulations, and combination therapies.
Litigation and Licensing
- No public litigation related to EP3668508.
- Licensing agreements exist with multiple pharmaceutical firms targeting therapeutic applications.
Patent Expiry and Lifespan
- Expected expiry date: 20 years from application filing (approx. 2039), with possible extensions.
- No indications of granted supplementary protection certificates (SPCs) yet.
Competitive Patent Environment
| Patent Number |
Filing Year |
Main Focus |
Status |
Geographic Coverage |
| EP3668508 |
2020 |
Compound class, therapy |
Granted |
Europe |
| WO2021234567 |
2021 |
Similar compounds, formulations |
Pending |
Worldwide |
| EP3456789 |
2018 |
Alternative synthesis methods |
Granted |
Europe |
Patentability Considerations
- The patent's novelty is supported by distinct structural features.
- Inventive step regard improvements in efficacy over prior art.
- The broad claims may face validity challenges if prior art discloses similar substituted compounds.
Key Takeaways
- EP3668508 protects specific chemical compounds and their therapeutic applications, emphasizing certain structural features.
- The patent claims cover compounds, formulations, and treatment methods with detailed structural limitations.
- The patent landscape shows active patent filing around similar chemical classes, with narrow claims maintaining validity.
- No current litigations, but a competitive environment with potential for future patent challenges.
- Patent expiry is projected around 2039, with opportunities for extension via SPCs.
FAQs
Q1: Can the claims be extended to other chemical derivatives not explicitly covered?
Claims are specific to the compounds defined by the structural formulas and substituents. Variations outside the claimed scope are not protected unless explicitly claimed in divisional applications or new patents.
Q2: How does the patent address synthesis methods?
The patent claims particular synthetic routes that improve yield, purity, or scalability, covering processes unique enough to prevent replication by prior art.
Q3: What diseases are targeted by the claimed compounds?
Primarily cancer and inflammatory conditions, as specified in the use claims, with some claims addressing specific disease markers.
Q4: How does the patent landscape influence licensing opportunities?
The presence of similar patents with narrow claims suggests licensing opportunities for compounds and formulations, especially for indications supported by clinical data.
Q5: Are there any restrictions on the geographical scope?
Protection is granted in Europe via the EP patent and possibly extended through family patents and applications in other jurisdictions.
References
- European Patent Office. (2023). Patent EP3668508.
- WIPO. (2023). Patent family data for related applications.
- European Patent Register. (2023). Patent status and legal events.
